The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial loss in body size and benefit metabolic health, particular